colony stimulating factor


Also found in: Dictionary, Acronyms, Wikipedia.

colony stimulating factor

n.
A hormone produced in the cells lining the blood vessels that stimulates the bone marrow to synthesize white blood cells.

colony stimulating factor

One of a number of glycoprotein factors that allow and promote the reproduction and differentiation of blood cells and their precursor cells.
References in periodicals archive ?
Most tantalizing to cancer researchers are the so-called colony stimulating factors (CSFs) and a hormone called erythropoeitin, each of which triggers proliferation of specific cells.
Patents for Hematopoietic Factors II-40 Hospira Receives EC Approval on Retacrit II-41 RLS to Initiate Clinical Trials of Erythropoietin II-41 InterMune Drops Phase III trial of Interferon II-41 Chugai to Conduct Additional Trial on Epogin[R] II-41 Merck KGaA Acquires Serono Labs II-41 CytoPharm Acquires Low-Dose Interferon License from Amarillo Biosciences II-42 Hospira Signs Agreements with STADA and BIOCEUTICALS for Erythropoietin II-42 Biocon Bags GEAC Approval to Conduct Clinical Trial of Granulocyte Colony Stimulating Factor II-42 SII to Conduct Clinical Trials of Rdna Products II-42 Claris to Construct Production Facility for EOP II-42 Mayne and Pliva to End Collaboration on Erythropoietin Development II-43 GeneMedix Collaborates with CJ Corp.
The two products, called colony stimulating factors, stimulate bone marrow to produce blood cells including neutrophils that reduce the bodys risk of developing an infection and decrease risk of death from acute radiation syndrome.
com hope to make the industry aware of some very interesting properties of Erythropoietin, Granulocyte Colony Stimulating Factor, and Growth Hormone, properties which were very surprising to us.
Nasdaq GM:NTEC) today announced that its partner, BioGeneriX AG, a company of the ratiopharm Group, has been notified by the regulatory authority in a Western European jurisdiction that it is cleared to initiate a first Phase I clinical trial for Neose's GlycoPEG-GCSF, a long-acting, GlycoPEGylated[TM] granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.
Neose's first two proprietary candidates are NE-180 and GlycoPEG-GCSF, a long-acting version of granulocyte colony stimulating factor (G-CSF).
Neose's first two proprietary candidates are NE-180 (GlycoPEG-EPO), a long-acting version of erythropoietin, and GlycoPEG-GCSF, a long-acting version of granulocyte colony stimulating factor (G-CSF).
Neose's first two proprietary candidates are NE-180 (GlycoPEG-EPO), a long-acting version of erythropoietin, and GlycoPEG- GCSF, a long-acting version of granulocyte colony stimulating factor (G-CSF).
The European Agency for the Evaluation of Medicinal Products has already developed draft guidelines for generic versions of insulin, human growth factor, epoetin and colony stimulating factors (CSFs).
The picture is changing today and biotechnology feeds innovative ideas to the pharmaceutical industry to produce products such as recombinant human insulin, growth hormone, monoclonal antibodies, granulocyte colony stimulating factors, erythropoeitin and interferon vaccines.
Biotechnology products already in use on the market include erythropoietin (EPO), granulocyte colony stimulating factors, growth hormone (GH), human insulin, and tissue plasminogen activator (TPA).
The report provides a comprehensive marketing and technological assessment, as well as medical rationale and diagnostic prospects, for the major categories of both circulating and cellular tests, such as Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines, Immunohistochemical Stains and others.

Full browser ?